ERBB2 (HER2) amplifications represent a clinical biomarker for HER2-inhibitor therapy, and many of the breakpoint patterns as observed in POG570 advanced cancers would conceivably have involved the primary cancer. The gene discussed is ERBB2; the disease is cancer.